--- title: "Hong Kong stocks' new economy rebounded across the board, with the pharmaceutical sector leading the gains" type: "News" locale: "en" url: "https://longbridge.com/en/news/282835498.md" description: "On April 15th, the Hong Kong stock market continued to rebound, with the pharmaceutical sector leading the gains, and technology and internet leaders also performing strongly. The CSI Hong Kong Connect Medical and Health Integration Index rose by 3.6%, the internet index increased by 1.4%, the new economy index climbed by 1.3%, and the technology index went up by 1.2%. The trading volume of the Hong Kong Connect Internet ETF reached HKD 700 million, indicating capital inflow. Risk warning: Investment should be cautious" datetime: "2026-04-15T11:24:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282835498.md) - [en](https://longbridge.com/en/news/282835498.md) - [zh-HK](https://longbridge.com/zh-HK/news/282835498.md) --- # Hong Kong stocks' new economy rebounded across the board, with the pharmaceutical sector leading the gains On April 15th, the Hong Kong stock market continued its rebound, with the new economy sector blooming in multiple areas, led by the pharmaceutical sector. Technology and internet leaders also strengthened simultaneously. By the close of the day, the CSI Hong Kong Connect Medical and Health Integration Index surged 3.6%; the CSI Hong Kong Connect Internet Index rose 1.4%, the Hang Seng Hong Kong Connect New Economy Index increased by 1.3%, and the Hang Seng Technology Index climbed 1.2%, while the CSI Hong Kong Connect Consumer Thematic Index slightly declined by 0.1%. According to WIND data, as of April 15th, from a valuation perspective: The rolling price-to-earnings ratio of the Hang Seng Hong Kong Connect New Economy Index is 24.8 times, with a valuation percentile of 54.8% since 2018; The rolling price-to-earnings ratio of the Hang Seng Technology Index is 22.2 times, with a valuation percentile of 25.6% since its release in 2020; The rolling price-to-earnings ratio of the CSI Hong Kong Connect Medical and Health Integration Index is 45.1 times, with a valuation percentile of 63.6% since 2017; The rolling price-to-earnings ratio of the CSI Hong Kong Connect Internet Index is 22.5 times, with a valuation percentile of only 13.9% since its release in 2021; The rolling price-to-earnings ratio of the CSI Hong Kong Connect Consumer Thematic Index is 15.9 times, with a valuation percentile of only 0.6% since its release in 2020, at a historically low level. In terms of capital, the Hong Kong Connect Internet ETF E Fund (513040, Connect A/C: 019313/019314) had a total trading volume of 700 million yuan throughout the day, significantly increasing compared to the previous trading day. Risk warning: Funds have risks, and investment should be cautious ### Related Stocks - [STECH.HK](https://longbridge.com/en/quote/STECH.HK.md) - [513770.CN](https://longbridge.com/en/quote/513770.CN.md) - [513040.CN](https://longbridge.com/en/quote/513040.CN.md) - [520630.CN](https://longbridge.com/en/quote/520630.CN.md) - [520910.CN](https://longbridge.com/en/quote/520910.CN.md) - [513200.CN](https://longbridge.com/en/quote/513200.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159137.CN](https://longbridge.com/en/quote/159137.CN.md) - [03032.HK](https://longbridge.com/en/quote/03032.HK.md) - [03088.HK](https://longbridge.com/en/quote/03088.HK.md) ## Related News & Research - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News](https://longbridge.com/en/news/286251150.md) - [Alibaba AI revenue sees triple-digit-gain streak hit 11 quarters amid reshuffle](https://longbridge.com/en/news/286280994.md) - [Alphamab Starts Phase III Trial of Next-Gen HER2 Drug in High-Risk Breast Cancer](https://longbridge.com/en/news/280228645.md)